A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Trial Profile

A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs MEDI 9197 (Primary) ; Durvalumab
  • Indications Cutaneous T cell lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 31 Jul 2017 Planned number of patients changed from 78 to 135.
    • 31 Jul 2017 Planned End Date changed from 13 Jun 2022 to 24 Jun 2020.
    • 31 Jul 2017 Planned primary completion date changed from 1 Jul 2021 to 24 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top